Clinical Trial Update: A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia. [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating luspatercept (ACE-536) in Chinese participants with beta-thalassemia who require regular red blood cell transfusions…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia

Drugs mentioned

• Luspatercept (luspatercept)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Beta-thalassemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING